DAY 1 - Saturday, October 22
Welcome
Ophthalmology Times welcomes ophthalmic professionals from around the world to Orlando. Our four-day coverage of this year’s meeting of the American Academy of Ophthalmology begins today and includes breaking news, the latest research findings, and reports of interest to readers.
Enjoy the meeting!
|
|
REFRACTIVE SUBSPECIALTY DAY
Surgeons weigh WFG ablation
Orlando—Leading refractive surgeons agree wavefront-guided (WFG) ablation is a significant advance in laser vision correction, but have different opinions about its role in treating myopic eyes with low higher-order aberrations (HOAs). » MORE
|
|
Data: ‘Stiffen the bulge’
Orlando—Results from a prospective clinical trial show that corneal collagen crosslinking (CXL) is a promising modality for treatment of keratoconus (KC) and postLASIK ectasia (PLE), said Peter S. Hersh, MD. » MORE
|
|
Old technique, new delivery
Orlando—Results of a preclinical pilot study demonstrate ocular iontophoresis accelerates transfer of topically applied riboflavin into the cornea compared with conventional application, said George O. Waring IV, MD. » MORE |
|
New corneal imaging superior?
Orlando—Placido corneal topography is established technology for corneal imaging, but whether it is the best diagnostic technique to detect forme fruste keratoconus (FFKC) when screening refractive surgery candidates is a matter of debate. » MORE
|
|
RETINA SUBSPECIALTY DAY
Results: CATT at 1 year
Orlando—A head-to-head comparison of ranibizumab (Lucentis, Genentech) and bevacizumab (Avastin, Genentech) in the Comparison of Age-related Macular Degeneration (AMD) Treatments Trials (CATT) indicated that at the 1-year time point, both drugs were clinically equivalent for treating the disease, said Daniel Martin, MD. » MORE
|
|
Ranibizumab inhibits VEGF
Orlando—The HORIZON Study for retinal vein occlusion (RVO), an extension study composed of patients treated in the BRAVO Study for branch retinal vein occlusion (BRVO) and the CRUISE study for central retinal vein occlusion (CRVO), showed that 0.5-mg intravitreal injections of ranibizumab (Lucentis, Genentech) inhibit vascular endothelial growth factor as in previous studies of the efficacy of the drug. » MORE
|
|
Radiation benefits AMD
Orlando—The MERITAGE Study (NeoVista), a study to evaluate the effect of epimacular brachytherapy in patients with exudative age-related macular degeneration (AMD) previously treated with ranibizumab (Lucentis, Genentech), showed that the treatment results of radiation therapy were “interesting and encouraging” at the 2-year time point, according to Pravin Dugel, MD. » MORE |
|
Drug noninferior for AMD
Orlando—Two studies of a fusion protein (VEGF Trap-Eye, Regeneron) showed that all doses of the drug, including those administered every 2 months, to treat neovascular age-related macular degeneration (AMD) were noninferior to ranibizumab (Lucentis, Genentech) in the number of patients who maintained their visual acuity. » MORE |
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
|
|
Exhibit Hall Hours
Saturday, October 22
9 a.m. – 5 p.m.
Sunday, October 23
9 a.m. – 5 p.m.
Monday, October 24
9 a.m. – 5 p.m.
Tuesday, October 25
9 a.m. – 3 p.m.
We welcome your feedback!
Please send your comments to:
Mark Dlugoss
Editor-in-Chief
Advanstar Eye Health Group
mdlugoss@advanstar.com |
|
